文献速递类风湿关节炎痛风与晶体性关节病其他结缔组织病

风湿病学中的治疗与肾脏

Therapeutics in rheumatology and the kidney.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

本综述探讨风湿病治疗药物在慢性肾脏病(CKD)背景下的安全性与有效性,涵盖非甾体抗炎药(NSAIDs)、糖皮质激素(CSs)、传统合成改善病情抗风湿药(DMARDs)、新型生物DMARDs和靶向合成DMARDs,并回顾CKD中的抗痛风处方,旨在为风湿科、肾内科和全科医生提供实践指导。

要点

  • 现代DMARDs的肾毒性潜力差异很大,在已有CKD人群中并非总是禁忌。
  • 综述涵盖NSAIDs、CSs、传统合成DMARDs、生物DMARDs、靶向合成DMARDs及抗痛风药在CKD中的使用。
  • 旨在为风湿科、肾内科和全科医生在CKD背景下处方这些药物提供实践指导。

核心结论

  • 现代DMARDs的肾毒性潜力差异很大,在已有CKD人群中并非总是禁忌。

研究设计与样本

  • 综述,探讨风湿病治疗药物在CKD背景下的安全性与有效性。

主要发现

  • 综述详细探讨了治疗风湿病药物在CKD背景下的安全性与有效性。
  • 讨论涵盖传统药物即NSAIDs、CSs和传统合成DMARDs,以及新型生物DMARDs和靶向合成DMARDs。
  • 还回顾了CKD中的抗痛风处方。

临床怎么用

  • 旨在为风湿科、肾内科和全科医生在CKD背景下处方这些药物提供实践指导。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The field of rheumatology has advanced significantly in recent years to provide rheumatologists with an extensive array of medications to combat rheumatic joint conditions. In contrast to an older era, when NSAIDs and other nephrotoxic agents were the mainstay of treatment, modern DMARDs vary considerably in their nephrotoxic potential and their use is not always precluded in populations with pre-existing chronic kidney disease (CKD). This review will explore in detail the safety and efficacy profiles of medications used to treat rheumatologic disease, specifically in the setting of CKD. Specifically, we discuss both traditional agents used, i.e. NSAIDs, CSs and conventional synthetic DMARDs, as well as novel biologic DMARDs and targeted synthetic DMARDs. Anti-gout prescribing in CKD is also reviewed. We aim to provide practical guidance to rheumatologists, nephrologists and general physicians when prescribing these medications in the setting of CKD.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Harty T, O'Shaughnessy M, Harney S, et al. Therapeutics in rheumatology and the kidney. Rheumatology (Oxford). 2023. PMID: 35951751. doi:10.1093/rheumatology/keac460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。